ライフサイエンスコーパス: p-

1 s was equally prevalent (90.2% versus 89.0%, p = 0.738).

2 s higher with PN vs. Controls (12.5% vs. 0%, p = 0.024).

3 tate changes, 77.1 +/- 7.3 vs 71.2 +/- 11.0, p = 0.043 FDR-corrected) than beginner chess players.

4 tate numbers, 75.8 +/- 7.9 vs 68.8 +/- 12.0, p = 0.043 FDR-corrected) and changes from one meta-state

5 8; p < 0.001) for NHB, 2.8 (95% CI 2.7, 3.0; p < 0.001) for Hispanic, 2.2 (95% CI 1.8, 2.6; p < 0.001

6 h AUC of its ROC as 0.92 (95% CI: 0.80-1.00, p = 0.001) with an ideal cut-off at 12.5 HU, where the s

7 l treatment (RR: 0.73; 95% CI: 0.53 to 1.00; p = 0.047) with a number needed to treat of 36 to preven

8 5% confidence interval (CI): - 0.12, - 0.01; p = 0.04; absolute difference: - 8.31; 95% CI: - 13.8, -

9 ment by time interaction (F((8,245)) = 2.02, p = 0.04), suggesting a prolongation of the antidepressa

10 sis predicted lower FAAH (F(1,26.95) = 6.03, p = .021, Cohen's f = 0.27, medium effect).

11 g behavior (d = -0.17; 95% CI: -0.30, -0.04; p = 0.012).

12 0.24, p = 1.8 x 10(-7) versus r(g) = -0.05, p = 0.39 in individuals not reporting trauma exposure, d

13 , 1.092; p = 0.059] and 1.008 [0.966, 1.052; p = 0.702], respectively).

14 D score revealed an AUC of 0.417 (SE = 0.07, p = 0.191).

15 027, 1.107; p = 0.001], 1.044 [1.007, 1.082; p = 0.017], and 1.190 [1.146, 1.235; p < 0.001], respect

16 (ARD: -7.30% points, 95% CI -10.50 to -4.09, p < 0.001).

17 ated with NO2 and PM10 (1.044 [0.998, 1.092; p = 0.059] and 1.008 [0.966, 1.052; p = 0.702], respecti

18 significantly more patients (72.7% vs 23.1% p = 0.04) despite overall larger baseline defect size (3

19 sttraumatic stress disorder (52.4% vs 37.1%; p = 0.03).

20 (5.3 days (5.1-5.5) vs 4.9 days (CI 4.8-5.1, p < 0.01).

21 atoduodenectomies compared < 60 (4% vs. 10%, p = 0.046).

22 8% (95% confidence interval [CI]: 6% to 10%; p < 0.001), soluble ST2 by 4% (95% CI: 1% to 7%; p = 0.0

23 difference: - 0.21; 95% CI: - 0.32, - 0.10; p = 0.003, respectively].

24 for NO2, PM10, and SO2 (1.066 [1.027, 1.107; p = 0.001], 1.044 [1.007, 1.082; p = 0.017], and 1.190 [

25 BMI (52.18 vs. 40.11, p = 0.001), insulin (19.35 vs. 8.80 mIU/L, p < 0.001) an

26 dient (16 mm Hg [sd, 6] vs 39 mm Hg SD, 11]; p < 0.001) and in the relationship of jugular venous bul

27 ed by type 2 MI (34.2%) and type 1 MI (12%) (p < 0.001).

28 ron (95% confidence interval [CI] = 17-127%, p = 0.004) than immunopattern III lesions, and 30% more

29 (>0.11 ml(-1) OR 3.067, 95% CI 1.825-5.128, p < 0.001).

30 for overall survival (Relative Risk: 2.129, p < 0.0001) and recurrence-free survival (Relative Risk:

31 (n = 3,673; aHR: 0.95; 95% CI: 0.79 to 1.13; p = 0.550).

32 rmed a DBP effect on AD (beta(GSMR) = -0.14, p = .03).

33 higher in Cit-B12 than placebo (33% vs 15%, p = 0.04).

34 (ARD: -3.74% points, 95% CI -5.31 to -2.16, p < 0.001); transactional sexual exploitation, 10.07% an

35 te difference: - 0.37; 95% CI: 0.54, - 0.19; p < 0.0001; and absolute difference: - 0.21; 95% CI: - 0

36 lation (odds ratio, 3.25; 95% CI, 2.52-4.19; p < 0.01) and vasopressors use (odds ratio, 1.42; 95% CI

37 vascular treatment (1.6% compared with 4.2%; p = 0.0071).

38 (32.7 +/- 19.5 mm(2) vs 21.5 +/- 10.7 mm(2), p = 0.11).

39 ay mortality by -1.6% (95% CI, -3.4 to -0.2, p = 0.039) and 90-day mortality by -2.3% (95% CI, -4.3 t

40 (ARD: -5.23% points, 95% CI -7.26 to -3.20, p < 0.001); physical abuse, 38.58% and 23.85% (ARD: -14.

41 59.35; p < 0.001), putamen (F(1,59) = 87.20; p < 0.001) and hippocampus (F(1,59) = 14.49; p < 0.001)

42 west of 7% (20/284) after refresher in 2017 (p = 0.001), increased again to an average of 9.6% (240/2

43 pothetical (d = -0.32; 95% CI: -0.44, -0.21; p < 0.001) and actual consumption and purchasing behavio

44 p = 0.02) and less often asthma (8% vs 23%; p < 0.01).

45 1.082; p = 0.017], and 1.190 [1.146, 1.235; p < 0.001], respectively) when highest and lowest pollut

46 uals reporting trauma exposure (r(g) = 0.24, p = 1.8 x 10(-7) versus r(g) = -0.05, p = 0.39 in indivi

47 and higher emotional exhaustion (r = 0.246; p = 0.0007).

48 ly associated with SO2 (1.207 [1.154, 1.262; p < 0.001]) but not significantly associated with NO2 an

49 lung tissue and gas recruitment (R = 0.266, p = 0.008, R = 0.357, p = 0.002, respectively).

50 Specialist palliative care (37% versus 27%, p = 0.002) and AD inclusion in hospital files (10% versu

51 roup, mean difference 9%, 95% CI -5% to 28%, p = 0.16).

52 primary diagnosis of pneumonia (41% vs 28%; p = 0.02) and less often asthma (8% vs 23%; p < 0.01).

53 urrence-free survival (Relative Risk: 1.299, p < 0.0001) in patients with HCC.

54 inclusion in hospital files (10% versus 3%, p < 0.001) were more likely in the intervention group.

55 ccipitotemporal cortex, and insula (Z > 2.3; p < 0.05; whole-brain corrected).

56 16.3 (95% confidence interval: 4.1 to 65.3; p < 0.0001).

57 , 95% confidence interval [CI] 10.10-106.31, p = 0.02) with increased risk of macrosomia (odds ratio

58 e IFG specific to the VAN (F(1,57) = 10.311, p = .002).

59 RD: -14.72% points, 95% CI -19.11 to -10.33, p < 0.001); emotional abuse, 25.39% and 12.98% (ARD: -12

60 34.85; p < 0.001), caudate (F(1,59) = 59.35; p < 0.001), putamen (F(1,59) = 87.20; p < 0.001) and hip

61 ecruitment (R = 0.266, p = 0.008, R = 0.357, p = 0.002, respectively).

62 ose without hydrosalpinx (95% CI: 1.02-4.36, p = 0.042).

63 main (rho = 0.40, p < 0.001, and rho = 0.38, p < 0.001).

64 cle number (MD 3.79%; 95% CI -9.81%, 17.39%; p = 0.585), and apolipoprotein A-1 (MD -1.83%; 95% CI -5

65 [25%]; risk ratio, 1.24; 95% CI, 1.10-1.39; p = 0.0004; I = 0%).

66 wild-type, 0.60 +/- 0.17 ms, n = 21 Kv3.3KO, p = 0.0001).

67 sk of subsequent admissions (72.6% vs 86.4%, p < 0.001) than those with NOM, with hazard ratio (HR) 0

68 ay mortality by -2.3% (95% CI, -4.3 to -0.4, p = 0.018).

69 aring 4+ ACEs with no ACEs was 2.0 (1.7-2.4, p < 0.001).

70 IBS total score and pain domain (rho = 0.40, p < 0.001, and rho = 0.38, p < 0.001).

71 1.18; 95% confidence interval: 0.99 to 1.41; p = 0.26).

72 sk of death (HR, 1.134; 95% CI, 0.894-1.438; p = 0.301) as non-traumatic AKI-RRT patients.

73 1.37; 95% confidence interval: 1.27 to 1.48; p < 0.0001).

74 p < 0.001) and hippocampus (F(1,59) = 14.49; p < 0.001) volumes.

75 1) and decreased in 40-64 years (78.0-73.5%, p = 0.001) during study period.

76 in the intervention period (15.3% vs. 3.5%; p < 0.001).

77 , 9.9; p < 0.001), and 7.0 (95% CI 6.6, 7.5; p < 0.001) for the corresponding age strata above, with

78 risk of operative mortality (2.4% vs. 0.51%; p = 0.007).

79 p < 0.001) and HOMA-IR index (6.48 to 2.52, p < 0.001) were reduced after surgery.

80 cale in critically ill patients (rho, -0.54; p = 0.036).

81 assessment (89.45 [19.32] vs 110.10 [19.54]; p < 0.01).

82 ely associated with increased TRV (r = 0.55, p < 0.005).

83 LG co-contraction (affected side, r = 0.557, p = 0.020; contralateral side, r = 0.627, p = 0.007) and

84 rotein A-1 (MD -1.83%; 95% CI -5.23%, 1.56%; p = 0.290).

85 utcome: odds ratio, 2.28 (95% CI, 2.03-2.57; p < 0.001).

86 zard ratio (HR), 0.473; 95% CI, 0.392-0.571; p < 0.001), but similar rates of ESKD (HR, 1.166; 95% CI

87 p = 0.34) or major bleeding (3.6% vs. 1.6%, p = 0.18).

88 CU at the time of diagnosis (21.0% vs. 8.6%, p = 0.024).

89 ican ancestry than controls (68.1% vs 58.6%; p = 5 x 10(-6)).

90 ide of collagen III by 3% (95% CI: 0% to 6%; p = 0.04) and increased carboxyl-terminal telopeptide of

91 n (Penetration Aspiration Scale score >= 6) (p = 0.016; odds ratio = 2.17; 95% CI 1.14-4.13) and with

92 < 0.001) for Hispanic, 2.2 (95% CI 1.8, 2.6; p < 0.001) for NHAIAN, and 1.6 (95% CI 1.4, 1.7; p < 0.0

93 7, p = 0.020; contralateral side, r = 0.627, p = 0.007) and the Oswestry disability index scores in L

94 tes of ESKD (HR, 1.166; 95% CI, 0.829-1.638; p = 0.377) and short-term risk of death (HR, 1.134; 95%

95 ing periplaque white matter (95% CI = 3-64%, p = 0.03).

96 of lower personal accomplishment (r = -1.64; p = 0.0255) and higher emotional exhaustion (r = 0.246;

97 d both subcortical tau pathology (R = 0.667, p = 0.003) and neuroinflammation (R = 0.788, p < 0.001).

98 CVR = 0.22 [95% CI, 0.06 to 0.39], z = 2.67; p = .008).

99 hose without antibodies (93.4% versus 78.7%, p < 0.001), whereas taste loss was equally prevalent (90

100 ent CT angiography (2.0% compared with 4.7%; p = 0.0017) or endovascular treatment (1.6% compared wit

101 0.001), soluble ST2 by 4% (95% CI: 1% to 7%; p = 0.002), and N-terminal propeptide of collagen III by

102 ncreased (Bias 18.71, CI 33.87-48.75, r 0.7, p < 0.0001).

103 0.001) for NHAIAN, and 1.6 (95% CI 1.4, 1.7; p < 0.001) for NHAP populations.

104 us NHW population were 7.0 (95% CI 5.8, 8.7; p < 0.001), 8.8 (95% CI 7.8, 9.9; p < 0.001), and 7.0 (9

105 nce interval] -1.91 minutes [-5.53 to 1.70], p = 0.316).

106 0.61; 95% confidence interval: 0.53 to 0.71; p < 0.001).

107 incongruent trials (TQ: Sobel test t = 1.73, p = .042) of the Cognitive Counting Task.

108 ride level (MD -1.51%; 95% CI -3.75%, 0.74%; p = 0.189), very-low-density lipoprotein particle number

109 west cessation rates (RR 0.55, CI 0.40-0.74; p < 0.001).

110 (ARD: -7.87% points, 95% CI -11.98 to -3.76, p < 0.001); and youth lawbreaking, 18.90% and 11.61% (AR

111 ter duration of illness (F(1,26.95) = 13.78, p = .001; Cohen's f = 0.39, medium to large effect) and

112 p = 0.003) and neuroinflammation (R = 0.788, p < 0.001).

113 ncreased in patients > 65 years (11.7-17.8%, p < 0.001) and decreased in 40-64 years (78.0-73.5%, p =

114 eated in tertiary hospitals (74.7% vs 45.8%; p < 0.0001).

115 of collagen type I by 4% (95% CI: 1% to 8%; p = 0.02) compared with valsartan alone, consistently in

116 rates of intracerebral hemorrhage (6% vs 8%; p = 0.35) did not differ.

117 s relative to NHW were 3.6 (95% CI 3.5, 3.8; p < 0.001) for NHB, 2.8 (95% CI 2.7, 3.0; p < 0.001) for

118 ARD: -12.41% points, 95% CI -16.00 to -8.83, p < 0.001); community violence victimisation, 36.25% and

119 rs use (odds ratio, 1.42; 95% CI, 1.10-1.83; p < 0.01) were independently associated with day 30 mort

120 difference: - 8.31; 95% CI: - 13.8, - 2.85; p = 0.003; absolute difference: - 0.37; 95% CI: 0.54, -

121 and reduction of thalamus (F(1,59) = 34.85; p < 0.001), caudate (F(1,59) = 59.35; p < 0.001), putame

122 less than in Europeans (ROC AUC 0.84 v 0.87, p < 0.0001).

123 0.77; 95% confidence interval: 0.68 to 0.88; p < 0.001) and all-cause-mortality (7.6% vs. 9.7%; adjus

124 mia (odds ratio [OR] 1.38, 95% CI 1.01-1.89, p = 0.04) versus neonates of insulin-treated mothers.

125 ment of lateral ventricles (F(1,59) = 48.89; p < 0.001) and reduction of thalamus (F(1,59) = 34.85; p

126 clinically relevant bleeding (4.8% vs. 2.9%, p = 0.34) or major bleeding (3.6% vs. 1.6%, p = 0.18).

127 0.0001), predominantly male (73.1% vs 53.9%; p < 0.0001), and more frequently treated in tertiary hos

128 5.8, 8.7; p < 0.001), 8.8 (95% CI 7.8, 9.9; p < 0.001), and 7.0 (95% CI 6.6, 7.5; p < 0.001) for the

129 (0.31-0.80)p= 0.004 for OS, 0.60 (0.40-0.90)p = 0.014 for DFS).

130 (n = 2,133; aHR: 0.71; 95% CI: 0.55 to 0.91; p = 0.006), but not among the other 2 phenotypes (Hp1 al

131 0.86; 95% confidence interval: 0.81 to 0.92; p < 0.001), with no significant interaction with treatme

132 ar sexual IPV (AOR: 0.73; 95% CI: 0.56-0.94, p = 0.014), and no intervention reduced perpetration of

133 emotional, salient stimuli (F(1,125) = 4.94, p = .028) and greater activity in the portion of the IFG

134 cholesterol (OR = 0.88; 95% CI = 0.81-0.95; p = 0.002) were inversely associated with ICH risk, no s

135 PASP; 95% confidence interval: 0.86 to 0.96; p = 0.0009).

136 tients (odds ratio, 2.35; 95% CI, 1.87-2.96; p < 0.0001) were analyzed.

137 r time (odds ratio, 0.96; 95% CI, 0.93-0.98; p = 0.001).

138 2; 95% confidence interval [CI] = 0.85-0.99; p = 0.03) and LDL cholesterol (OR = 0.88; 95% CI = 0.81-

139 nset (RR per year 0.983; 95% CI 0.968-0.998; p = 0.002 for trend).

140 ents had lower levels of GABA in dorsal ACC (p = .03), and the subgroup of patients with a schizophre

141 au, and Timp1) in Mus as compared to Acomys (p < .05).

142 roteobacteria [p = 0.01] and Actinobacteria [p = 0.02]) and two families (Moraxellaceae [p < 0.001] a

143 rall, lactobacilli suppressed IL-6 (adjusted p < 0.001) and IL-8 (adjusted p = 0.0170) responses to G

144 IL-6 (adjusted p < 0.001) and IL-8 (adjusted p = 0.0170) responses to G. vaginalis.

145 erlipidemia, and chronic kidney disease (all p < 0.001).

146 bscale, total cholesterol and education (all p < 0.05) were the influencing factors of high BMI.

147 decreased probability of discharge home (all p < 0.001).

148 as all crashes or at-fault crashes only (all p > 0.05).

149 1.76-fold, and 2.34-fold, respectively (all p <= 0.02).

150 d with worse post-explantation survival (all p > 0.05).

151 tcomes, including age at loss of ambulation (p < 0.001).

152 total phenolic and soluble protein amounts (p < 0.05).

153 control subjects on multivariable analysis (p > .05).

154 of the drug for three weeks (p < 0.0001, and p = 0.001 for sacituzumab govitecan vs naked antibody, a

155 with ASD and ADHD diagnoses (p = 0.0006 and p = 0.002, respectively).

156 sed Stop-signal reaction time; p = 0.031 and p = 0.053 respectively).

157 d total mRNFL symmetry values (p = 0.047 and p = 0.040, respectively).

158 V complete visualization rates (p = 0.30 and p = 0.14).

159 s and 12 of 13 (92.5%) with AQP4 antibodies (p < 0.001).

160 entified 5,552 trait-variant associations at p < 5 x 10(-9), including 71 novel associations not foun

161 However, SNA, resting HR, HRV, and atrial (p = 0.03) and ventricular (p = 0.03) proarrhythmia persi

162 oved up to month 18 in both groups (Cit-B12, p < 0.0001; controls, < 0.0001-0.03); improvement at mon

163 ations also proved to be more bioaccessible (p < 0.05).

164 t loss and cachexia were significantly (both p < 0.05) greater and there was a trend (p < 0.10) for l

165 s were found for HDL and triglycerides (both p > 0.05).

166 n the cerebellum of postmortem human brains (p = 4.7e-5).

167 to females have lower replicative capacity (p = 0.0005) and are more type I interferon-resistant (p

168 nts and patients with dissection, right CCA (p = 0.000), ICA (p = 0.001), ECA (p = 0.004) diameters,

169 .001), ECA (p = 0.004) diameters, total CCA (p = 0.001), ICA (p = 0.009), and ECA (p = 0.003) diamete

170 l [CI] 5-29, 49-69 versus 70-82 months, chi2 p = 0.001) and 15 fewer months of overall survival (OS;

171 -1 to 31, 92-120 versus 113-129 months, chi2 p = 0.036).

172 significantly more effaced basilar cisterns (p = 0.0008).

173 were most relevant to both classifications (p <= 0.044).

174 cteriaceae (p = 0.002) and Escherichia coli (p = 0.033).

175 ession (p < 0.001) and cellular ATP content (p < 0.001) in sepsis patients.

176 findings compared to 33/125 (26%) controls (p = 0.248).

177 differed when compared to those of controls (p < 0.05, chi-squared test).

178 and advance increased from 109 to 160 days (p = .004).

179 670.8 +/- 183.5 days vs 885.1 +/- 78.4 days; p = 0.007).

180 duced, but there was a significant decrease (p < 0.001) in the power of slow oscillations and increas

181 Also, the fermented LFs showed decreased (p < 0.05) water absorption capacity but increased swelli

182 reviously implicated in axonal degeneration (p = 1.76 x 10(-08) with amyotrophic lateral sclerosis).

183 mors (p = 0.045), and peripheral deposition (p < 0.0001) of Lipiodol showed improved response.

184 logic complications (3/61 vs 10/53 for DHCA; p < 0.05) but not complications in other organ systems.

185 hips were found with ASD and ADHD diagnoses (p = 0.0006 and p = 0.002, respectively).

186 ls not reporting trauma exposure, difference p = 2.3 x 10(-4)).

187 Significant differences (p < 0.0001) were observed between the beef elemental con

188 dl IQR 4.65 dl vs. 7.51 dl vs. IQR 5.39 dl, p = 0.039).

189 .14)mg/dL vs. control: 0.09(-0.03,0.22)mg/dL;p = 0.797).

190 NAc-paracingulate gyrus for social domains (p < 0.001).

191 ociated with acenocoumarol maintenance dose (p < 0.05).

192 onary vascular resistance (-83 +/- 33 dynes; p = 0.07).

193 right CCA (p = 0.000), ICA (p = 0.001), ECA (p = 0.004) diameters, total CCA (p = 0.001), ICA (p = 0.

194 l CCA (p = 0.001), ICA (p = 0.009), and ECA (p = 0.003) diameters were also found to be different.

195 e same model, apoB retained a robust effect (p < 0.05), whereas the estimate for LDL cholesterol was

196 n increase in the family Enterobacteriaceae (p = 0.002) and Escherichia coli (p = 0.033).

197 copy numbers (p < 0.001), mtND1 expression (p < 0.001) and cellular ATP content (p < 0.001) in sepsi

198 progressively decreased with age in females (p = 0.029), with a non-significant increase in males (p

199 0.001; <= 1 consecutive days: 0.68 d fewer, p < 0.001).

200 p = 0.010; 2 consecutive days: 0.77 d fewer, p < 0.001; <= 1 consecutive days: 0.68 d fewer, p < 0.00

201 h of stay (3 consecutive days: 0.46 d fewer, p = 0.010; 2 consecutive days: 0.77 d fewer, p < 0.001;

202 ibration curves (five-parameter logistic fit p < 0.05) by plotting the measured ratios of the MS ion

203 aried from 59 (US) to 69 mm (Nancy, France) (p < 0.001), 25.3% of patients having a diameter of < 60

204 significantly with NAT2 acetylator genotype (p < 0.0001).

205 total nitrogen (p < 0.001), and beta-glucan (p < 0.01).

206 teria in the congestive heart failure group (p = 0.014), particularly due to an increase in the famil

207 0.9 to 0.69 +/- 1.2 in the PKE + NPDS group (p < .001).

208 1.1 to 0.49 +/- 1.0 in the PKE + XEN group (p < .001) and from 2.93 +/- 0.9 to 0.69 +/- 1.2 in the P

209 a medications did not change in both groups (p > 0.05) and showed no significant difference between t

210 e between the highest and lowest REA groups (p <= 0.05).

211 gnificant difference between the two groups (p > 0.05).

212 serum aldosterone were 6.8 vs. 5.5 ng/mL/h (p = 0.002) and 654 vs. 473 pg/mL (p = 0.01), respectivel

213 onary arterial pressure (-6.5 +/- 1.8 mm Hg; p = 0.005) and tended to decrease pulmonary vascular res

214 ted least squares mean: -4.0 vs. -0.9 mm Hg; p = 0.006), a change that was associated with reduced ri

215 urther substantiated by detection of higher (p < 0.01) concentrations of interferon-gamma in plasma o

216 ultrasound images were significantly higher (p < 0.05) in the longitudinal view than in the transvers

217 Also, homogeneous (p = 0.0006), non-sparse (p < 0.0001), rim deposition wit

218 increased from baseline by 7.8% at 24 hours (p = 0.022) and 15.0% at 48 hours (p = 0.0001) for patien

219 24 hours (p = 0.022) and 15.0% at 48 hours (p = 0.0001) for patients receiving bilateral stimulation

220 with dissection, right CCA (p = 0.000), ICA (p = 0.001), ECA (p = 0.004) diameters, total CCA (p = 0.

221 .004) diameters, total CCA (p = 0.001), ICA (p = 0.009), and ECA (p = 0.003) diameters were also foun

222 the power of slow oscillations and increase (p < 0.001) in cortical complexity, which was similar to

223 VAT ex-vivo lipolysis was increased (p < 0.05) in P-HFHS compared to P-CD dams.

224 er 0.1 stress hyperglycemia ratio increment; p < 0.001) and glycosylated hemoglobin greater than or e

225 er 0.1 stress hyperglycemia ratio increment; p = 0.005).

226 ficantly reduced its water absorption index (p <= 0.05).

227 ociated with altered white matter integrity (p = 2.5x10-7) in brain images from 1,738 young healthy a

228 r Open Access versus closed access journals (p = 0.320, 95% CI - 0.015, 0.046, adjusted mean false di

229 , p = 0.001), insulin (19.35 vs. 8.80 mIU/L, p < 0.001) and HOMA-IR index (6.48 to 2.52, p < 0.001) w

230 levels correlated with lower sodium levels (p = 0.017).

231 6 (main effect: 1.29 <= OR <= 2.91, 0.005 <= p <= 0.04, 11.8 <= MAF <= 40.9%), and implicated its int

232 ), with a non-significant increase in males (p = 0.092).

233 ) and more likely to have diabetes mellitus (p = 0.004), hypertension, hyperlipidemia, and chronic ki

234 6.3% (37/591) after the start of mentorship (p = 0.019).

235 d the three echocardiography gating methods (p > 0.05 for all).

236 rvival analysis, TNM stage (p < 0.01), mGPS (p < 0.05), NLR (p < 0.01), MUST (p <= 0.001), Low SMD (p

237 5 ng/mL/h (p = 0.002) and 654 vs. 473 pg/mL (p = 0.01), respectively.

238 icated in the Q175 Htt knock-in mouse model (p = 6.0 x 10(-8)) and in the transgenic sheep model (p =

239 x 10(-8)) and in the transgenic sheep model (p = 2.4 x 10(-88)).

240 everity groups (severe: p = 0.001, moderate: p = 0.02).

241 [p = 0.02]) and two families (Moraxellaceae [p < 0.001] and Pseudomonadaceae [p = 0.01]).

242 = 0.04) and 10 (69 +/- 4 ms to 62 +/- 3 ms; p < 0.001) miles.

243 after running 3 (65 +/- 3 ms to 62 +/- 3 ms; p = 0.04) and 10 (69 +/- 4 ms to 62 +/- 3 ms; p < 0.001)

244 le activity (all seven measured leg muscles (p >= 0.146)), soleus active muscle volume (p = 0.538; d

245 .01), mGPS (p < 0.05), NLR (p < 0.01), MUST (p <= 0.001), Low SMD (p < 0.05), SUVmax (p <= 0.001) and

246 13) for patients with grade < 3 neutropenia (p = 0.04; HR 0.44).

247 macromolecular distribution, total nitrogen (p < 0.001), and beta-glucan (p < 0.01).

248 TNM stage (p < 0.01), mGPS (p < 0.05), NLR (p < 0.01), MUST (p <= 0.001), Low SMD (p < 0.05), SUVmax

249 0 +/- 2.8 Nm, non-dominant: 3.9 +/- 2.7 Nm) (p < 0.001).

250 7 +/- 3.1 Nm, non-dominant: 3.4 +/- 2.8 Nm) (p < 0.001) and multi-to-multi-joint condition (dominant:

251 morolone-treated trial participants did not (p < 0.001; LS mean 15.86 [95% CI 8.51, 23.22]).

252 ied by lower mitochondrial DNA copy numbers (p < 0.001), mtND1 expression (p < 0.001) and cellular AT

253 ng Wilcoxon signed rank test with a value of p < 0.05 considered statistically significant.

254 spanic White > Asian/Pacific Islander/Other; p < 0.01), with higher levels of BDE-100 and BDE-153 amo

255 402 Mg C/ha less than their rain-fed pairs (p < .0001).

256 compared with 31.1% for the ND participants (p = .02).

257 ociated with higher levels of Porphyromonas (p < 0.05) and Prevotella.

258 me (p = 0.538; d = 0.241), or aerobic power (p = 0.458; d = 0.04) during running.

259 Ultrasound depth is a significant predictor (p = 0.044) of a histologically non-benign lipoma.

260 ion gradient to cerebral perfusion pressure (p = 0.004) when comparing normoxia to hypoxia.

261 ges from mucus in two phyla (Proteobacteria [p = 0.01] and Actinobacteria [p = 0.02]) and two familie

262 axellaceae [p < 0.001] and Pseudomonadaceae [p = 0.01]).

263 ociation to AV complete visualization rates (p = 0.30 and p = 0.14).

264 5) and are more type I interferon-resistant (p = 0.007) than those transmitted to males.

265 f 69.7 (21.2) and 60.7 (26.3), respectively (p = 0.029).

266 8.5 ng/mL at 24 and 48 weeks, respectively (p < 0.001).

267 toxanthin, and control groups, respectively; p < 0.001).

268 locus on chromosome 8 (lead SNP rs17052966, p = 4.53 x 10(-9), odds ratio = 1.28, se = 0.04).

269 reliability and accuracy were all the same (p = 0.001).

270 ficant difference in patients' satisfaction (p = 0.164).

271 to the other two MS severity groups (severe: p = 0.001, moderate: p = 0.02).

272 family-wise error rate (FWER) significance (p < 1.25E-06).

273 lteplase dose was statistically significant (p = 0.018).

274 ifference was not statistically significant (p = 0.183).

275 Serum progesterone level was significantly (p = 0.026) elevated at day + 7 of transplantation, while

276 allic, and ferulic acids were significantly (p < 0.05) increased in FIR dried samples.

277 NLR (p < 0.01), MUST (p <= 0.001), Low SMD (p < 0.05), SUVmax (p <= 0.001) and TLG (p < 0.001) were

278 Also, homogeneous (p = 0.0006), non-sparse (p < 0.0001), rim deposition within sparse tumors (p = 0.

279 On univariate survival analysis, TNM stage (p < 0.01), mGPS (p < 0.05), NLR (p < 0.01), MUST (p <= 0

280 Patients were 9.5 years older than suspects (p = 0.015).

281 ST (p <= 0.001), Low SMD (p < 0.05), SUVmax (p <= 0.001) and TLG (p < 0.001) were associated with ove

282 le in the development of the nervous system (p = 4.29 x 10(-11) with neuroticism), as well as SARM1,

283 sis had higher glutamate levels in thalamus (p = .01), but Glx levels in dorsal ACC and thalamus did

284 l (i.e. increased Stop-signal reaction time; p = 0.031 and p = 0.053 respectively).

285 of developing laryngeal granulation tissue (p = 0.02).

286 SMD (p < 0.05), SUVmax (p <= 0.001) and TLG (p < 0.001) were associated with overall survival.

287 oth p < 0.05) greater and there was a trend (p < 0.10) for lower serum 25(OH)D concentrations in the

288 at there were significant increasing trends (p <= 0.05) in annual precipitation near the south coasta

289 .0001), rim deposition within sparse tumors (p = 0.045), and peripheral deposition (p < 0.0001) of Li

290 om 40% of TEVARs in the US to 72% in the UK (p < 0.001).Mean intact TAA (iTAA) diameter varied from 5

291 nd superior and total mRNFL symmetry values (p = 0.047 and p = 0.040, respectively).

292 owed that there were significant variations (p < 0.001) for all assessed quantitative traits.

293 HRV, and atrial (p = 0.03) and ventricular (p = 0.03) proarrhythmia persisted.

294 (p >= 0.146)), soleus active muscle volume (p = 0.538; d = 0.241), or aerobic power (p = 0.458; d =

295 3.56 +/- 1.78 weeks vs 5.87 +/- 2.20 weeks (p = 0.01) and achieved complete epithelialization in sig

296 administration of the drug for three weeks (p < 0.0001, and p = 0.001 for sacituzumab govitecan vs n

297 f >= N(theta) clusters had deteriorated with p < p(Cluster), chosen empirically to give 95% specifici

298 ce of the second ITA target-77% at 15 years (p = 0.70) for the important and less important targets,

299 SD age: 67.8 +/- 8.9 vs. 66.1 +/- 8.2 years; p < 0.001) and more likely to have diabetes mellitus (p

300 younger (49.0 +/- 21.6 vs 60.6 +/- 18.7 yr; p < 0.0001), predominantly male (73.1% vs 53.9%; p < 0.0